Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

Selinexor is an oral, small molecule inhibitor of the nuclear export protein exportin 1 with demonstrated activity in hematologic and solid malignancies. Side effects associated with selinexor include nausea, vomiting, fatigue, diarrhea, decreased appetite, weight loss, thrombocytopenia, neutropenia...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Leukemia
Autores principales: Gavriatopoulou, Maria, Chari, Ajai, Chen, Christine, Bahlis, Nizar, Vogl, Dan T., Jakubowiak, Andrzej, Dingli, David, Cornell, Robert F., Hofmeister, Craig C., Siegel, David, Berdeja, Jesus G., Reece, Donna, White, Darrell, Lentzsch, Suzanne, Gasparetto, Cristina, Huff, Carol Ann, Jagannath, Sundar, Baz, Rachid, Nooka, Ajay K., Richter, Joshua, Abonour, Rafat, Parker, Terri L., Yee, Andrew J., Moreau, Philippe, Lonial, Sagar, Tuchman, Sascha, Weisel, Katja C., Mohty, Mohamad, Choquet, Sylvain, Unger, T. J., Li, Kai, Chai, Yi, Li, Lingling, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., Dimopoulos, Meletios Athanasios
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7449872/
https://ncbi.nlm.nih.gov/pubmed/32094461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-020-0756-6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares